Supplemental Table 1. Six-month Effect (95% CI) of 4 g/d Lovaza Treatment versus Placebo in Post MI Patients (Excluding 36 Patients with History of Prior MI at Baseline)

	LVESVI	Non-Infarct Myocardial Fibrosis	Infarct Size	LVEF
ITT Analysis (GLMM†)	**-7.2% (-11.9%, -2.2%)** **P = 0.0056**, N = 322	**-5.9% (-10.9%, -0.9%)** **P = 0.020**, N = 322	-4.6% (-20.0%, 13.7%) P = 0.60, N = 322	2.8% (-0.2%, 5.7%) P = 0.073, N = 322
Per Protocol Analysis (t-test‡)	**-7.7% (-12.8%, -2.7%)** **P = 0.0028**, N = 221	**-5.4% (-10.6%, -0.3%)** **P = 0.036**, N = 152	-8.2% (-21.4%, 5.0%) P = 0.22, N = 228	2.8% (-0.4%, 6.0%) P = 0.083, N = 221

ITT was defined as intention-to-treat, LVEF left ventricular ejection fraction, and LVESVI left ventricular end-systolic volume index.

† The general linear mixed model (GLMM) produces unbiased estimates for responses with missing data (see statistical analysis). LVESVI and Infarct Size were natural logarithm transformed to reduce skewness and/or heteroscedasticity of residuals. Estimates are relative changes.

‡ The per protocol analysis only included patients that attended both visits. No transformations were required, instead Satterthwaite approximation was used for heteroscedasticity. Estimates are relative changes.

Supplemental Table 2. Adjusted Analysis for Six-month Effect (95% CI) of 4 g/d Lovaza Treatment versus Placebo in Post MI Patients by Intention-to-treat Analysis

	LVESVI†	Non-Infarct Myocardial Fibrosis	Infarct Size†¶	LVEF
Model 0*	**-5.8% (-10.3%, -1.1%)** **P=0.017**	**-5.6% (-10.4%, -0.9%)** **P=0.022**	-3.4% (-17.8%, 13.6%) P=0.68	2.4% (-0.4%, 5.2%) P=0.094
Model 1Φ	**-5.4% (-10.1%, -0.6%)** **P=0.030**	**-5.0% (-10.1%, 0.0%)** **P=0.046**	1.9% (-13.2%, 19.7%) P=0.81	2.0% (-0.9%, 5.0%) P=0.16
Model 2§	**-5.7% (-10.4%, -0.9%)** **P=0.021**	-4.7% (-9.7%, 0.3%) P=0.067	2.2% (-13.3%, 20.3%) P=0.80	2.2% (-0.7%, 5.2%) P=0.14

LVEF left ventricular ejection fraction, and LVESVI left ventricular end-systolic volume index.

*Model 0 (N=358) demonstrates unadjusted analysis of O-3FA treatment versus placebo for the primary and secondary study endpoints

ΦModel 1 (N=354) demonstrates Model 0 adjusted for fixed covariates, including age, gender, race, enrolling site, pre-treatment omega-3 index, and pre-treatment log transformed infarct mass.

§Model 2 (N=326) demonstrates Model 1 additionally adjusted for medical therapy (renin-angiotensin system blockade, β-adrenergic–receptor antagonists, dual antiplatelet therapy, hydroxymethylglutaryl–coenzyme A reductase inhibitors), and baseline coronary heart disease risk factors (diabetes mellitus, hypertension, hypercholesterolemia, body mass index, active smoking, and heart rate.)

¶Infarct mass (pre-treatment) was not included in these models.

†Natural logarithm transformation was used to improve normality and/or homoscedasticity of residuals.